



VACCINE ACCESS TEST

Score Summary: CureVac

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. This is the fastest way to end the pandemic. So we want to know: **do world leaders' actions move us closer to, or further from, an equitable outcome?** The Vaccine Access Test provides a framework to answer this question based on the following metrics:

- **Support for & Collaboration with ACT-A:** Has this company collaborated with or provided financial support?
- **Transparency & Knowledge Sharing:** Has the company committed to non-profit and/or tiered pricing? Does this company share relevant knowledge and data to enable widespread access?
- **Multilateral Leadership:** Has leadership expended political capital to motivate cooperation on equity?
- **Deals:** Each deal this company has made to secure promising COVID-19 vaccine candidates is scored individually based on a set of metrics for how well they advance equity.

Each metric is worth up to 3 points and Deal Scores can earn up to 6 points. **CureVac can earn up to 15 points.**

METRIC	SCORE	RATIONALE
ACT-A 	0	CureVac is a CEPI-supported vaccine candidate with the prospect of being included in the COVAX Facility, but has not made any commitments yet.
Transparency & Knowledge Sharing 	0	CureVac ruled out selling its vaccine at cost, opting instead for an "ethical margin" for shareholders. CureVac also has not committed to sharing knowledge. The company may need to share information if it does not develop a successful vaccine candidate by late 2021, due to conditions in a research grant from the German government.
Multilateral Leadership 	0	CureVac has not used political capital to advance equity globally.
Deal Score (average)	1	CureVac has completed 1 deal with the EC, with a Deal Score of 1.

Total Score: 1 out of 15

CureVac's actions so far have not demonstrated dedication to equitable outcomes and advancing equity.

CureVac can improve its score by collaborating with the ACT-A, committing to non-profit pricing, abiding by funder CEPI's equitable access policy, and sharing relevant knowledge, intellectual property and data to enable wide scale production, distribution and use of vaccines, as outlined in the WHO's Solidarity Call to Action.



▲ Impeding Equity

Advancing Equity ▲